In this on-demand webinar, learn how to shift the paradigm on integrated evidence generation.
The growth of Real-World Evidence (RWE) from sources including patient registries, claims data, electronic medical records, digital health technologies and more has powered the ability of Medical Affairs to drive patient outcomes. Here, the MAPS Executive Consortium describes how.
In this episode, we hear from RWE and industry experts on the importance of early alignment of your evidence generation plan and medical strategy and how to integrate RWE into your publication plan.
This presentation looks at different regulatory contexts in which product developers are using RWE.
MAPS speaks with Stefan C. Weiss, MD, Managing Director, Dermatology at OM1 about EMR patient data overlain with technology to create a more accurate and equitable view of post-market safety.
This virtual presentation focuses on 3 aspects of RWE: What are RWE and Real-World Data (RWD), and how are they different? What are relevant legal and regulatory considerations associated with using RWE for product label expansion? How have applicants successfully used RWE to obtain approval for new drug and medical device indications?
On today’s episode of the MAPS “Elevate” podcast, we’re discussing the use of Real-World Evidence to understand and possibly intercede in treatment-resistant depression and why is it especially difficult to develop treatments against resistant depression using the traditional structure of R&D-led clinical trials.
At the MAPS 2022 Global Annual Meeting, we sat down with Riad Dirani and Omar Dabbous to chat about the structure and activities of HEOR within Medical Affairs.
This podcast episode details 4 things Field Medical teams can do better to overcome their organizations’ struggles to engage and support external experts.
This podcast explores the necessity to consider communication as an essential element in the planning process for RWE studies.